A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

NCT00841191 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
Pancreatic Neoplasms
Colorectal Neoplasms
Head and Neck Neoplasms
Lung Neoplasms

Interventions

DRUG: CNTO 328; Anti-interleukin-6 monoclonal antibody
DRUG: CNTO 328; Anti-interleukin-6 monoclonal antibody
DRUG: CNTO 328; Anti-interleukin-6 monoclonal antibody
DRUG: CNTO 328; Anti-interleukin-6 monoclonal antibody
DRUG: CNTO 328; Anti-interleukin-6 monoclonal antibody
DRUG: CNTO 328; Anti-interleukin-6 monoclonal antibody
DRUG: CNTO 328; Anti-interleukin-6 monoclonal antibody

Sponsor

Centocor, Inc.